Yunnan Botanee Bio-Technology Group Co.LTD

Equities

300957

CNE100004G74

Personal Products

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
58.06 CNY -0.53% Intraday chart for Yunnan Botanee Bio-Technology Group Co.LTD +2.80% -14.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023. CI
Certain A Shares of Yunnan Botanee Bio-Technology Group Co.LTD are subject to a Lock-Up Agreement Ending on 25-MAR-2024. CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Yunnan Botanee Bio-Technology Group Co.LTD CI
Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd. CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023. CI
In China's slowing beauty market, big brand discounts won't cut it RE
Shanghai Weimu Medical Technology Co., Ltd. announced that it has received CNY 100 million in funding from Yunnan Botanee Bio-Technology Group Co.LTD, Huajin Avenue Investment Co., Ltd., SHAREWIN Equity Investment and Management Co., Ltd., Shanghai CS Capital Co., Ltd, Sinvo Capital Holdings Co., Ltd., Investment Arm, IDG Capital Partners Co., Ltd. CI
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 87 Yuan From 105 Yuan, Keeps at Hold MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Increase in Equity Buyback. CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from Yunnan Botanee Bio-Technology Group Co.LTD CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Equity Buyback for CNY 200 million worth of its shares. CI
Yunnan Botanee Bio-Technology Group Co.LTD authorizes a Buyback Plan. CI
Yunnan Botanee’s H1 Profit Jumps 14% as Revenue Grows 15.5% MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Ruishi Health Technology Co., Ltd. announced that it has received CNY 100 million in funding from BRV Partners, LLC, Yaojin Private Equity Fund Management Co., Ltd., Sinovation Ventures Enterprise Management Limited, Yunnan Botanee Bio-Technology Group Co.LTD CI
Yunnan Botanee Seeks to Double Revenue in Three Years MT
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 105 Yuan From 132 Yuan, Keeps at Hold MT
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 132 Yuan From 145 Yuan, Keeps at Hold MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jeffries Downgrades Yunnan Botanee Bio-Technology to Hold From Buy, Adjusts Price Target to 145 Yuan From 200 Yuan MT
Jefferies Adjusts Yunnan Botanee Bio-Technology Group's Price Target to 200 Yuan From 220 Yuan, Keeps at Buy MT
Yunnan Botanee’s Q3 Profit Jumps 35.5% as Revenue Rises 21%; Shares Rally 12% MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Yunnan Botanee Bio-Technology Group Co.LTD(XSEC:300957) added to S&P Global BMI Index CI
Chart Yunnan Botanee Bio-Technology Group Co.LTD
More charts
Yunnan Botanee Bio-Technology Group Co LTD is a Chinese company mainly engaged in the production of cosmetics. The Company adopts a sales model based on offline channel sales and online channel sales as the leading factor. The Company's products mainly include creams, skin care lotions, facial masks, essences, lotions and other skin care products and make-up products such as isolation creams, blemish balm (BB) creams, and makeup removers. The Company is also engaged in the research and development, production and sales of skin care-related medical device products, mainly including hyaluronic acid repairing biofilm, hyaluronic acid repairing dressings, mainly used for the protection of skin with damaged barriers after minimally invasive surgery and care.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
58.06 CNY
Average target price
90.33 CNY
Spread / Average Target
+55.59%
Consensus
  1. Stock Market
  2. Equities
  3. 300957 Stock
  4. News Yunnan Botanee Bio-Technology Group Co.LTD
  5. Yunnan Botanee Bio-Tech Bumps Final Dividend by 337% on Stellar 2021 Earnings